Asia-Pacific Blood Culture Tests Market

Asia-Pacific Blood Culture Tests Market Size (2023 to 2028)

The Asia-Pacific Blood Culture Tests market is anticipated to grow at 9.21% CAGR from 2023 to 2028. It is estimated that the Asia-Pacific market was valued at USD 13.44 billion in 2023 and is expected to reach USD 20.88 billion by 2028.

Blood culture tests are laboratory tests done to examine a blood sample for the presence of bacteria or any other microorganisms. According to the World Health Organization, the global burden of infectious diseases accounts for 43%. High mortality and morbidity are associated with sepsis. This scenario demands highly advanced blood culture tests to detect the disease-causing microorganisms, which will aid inappropriate treatment.

The increase in the aging population with more need for blood tests is one of the significant factors contributing to the development of this market. Rising incidences of blood infections, increasing prevalence of infectious diseases, advanced technologies, and high demand for rapid diagnostic tests are a few of the factors driving the growth of this industry. Moreover, the rising incidences of drug-resistant strains of bacteria would further increase the demand for advanced blood culture tests.

The major factors that hinder the growth of the blood culture tests market are the high costs associated with highly automated blood tests, stringent regulations for approval, scarcity of qualified healthcare professionals to work with the latest technologies, unsuitable reimbursement policies, and the lack of awareness relating to the various technological advancements in the field.

This research report on the Asia Pacific Blood Culture Tests Market has been segmented & sub-segmented into the following categories:

By Product:

• Consumables
  • Blood Culture Media   
    • Aerobic Blood Culture Media
    • Pediatric Aerobic Blood Culture Media
    • Anaerobic Blood Culture Media
    • Mycobacterial Blood Culture Media
    • Fungi Blood Culture Media
  • Assay Kits & Reagents  
  • Blood Culture Accessories
• Instruments
  • Automated Blood Culture Systems    
  • Supporting Laboratory Equipment    
    • Incubators
    • Colony Counters
    • Microscopes
    • Gram Stainers
• Software and Services

By Technology:

• Culture-Based Technology
• Molecular Technologies
  • Microarrays
  • PCR (Polymerase Chain Reaction)    
  • PNA-FiSH (Peptide Nucleic Acid – Fluorescent in Situ Hybridization)    
• Proteomics Technology   

By Application:

• Bacteremia
• Fungemia
• Mycobacterial Detection

By End User:

• Hospital Laboratories
• Reference Laboratories

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore

Asia Pacific region is projected to register the highest CAGR during the forecast period, mainly due to the high occurrence of infectious diseases and developing healthcare infrastructure. Many diagnostic companies are targeting Asian countries like India and China for business expansion. The presence of a large base of the target population and an increase in the disposable income in the Asia Pacific region are some of the main factors aiding market growth. Accessibility of advanced diagnostics products and highly developed healthcare infrastructure have further fueled the growth market. Also, growing investments in R&D by manufacturers for new product development in this region is expected to propel the growth of the industry.

The Asia-Pacific Blood Culture Tests market is dominated by companies like Becton, Dickinson and Company, bioMérieux SA, Thermo Fisher Scientific Inc., Cepheid, Inc., Nanosphere Inc., IRIDICA, Beckman Coulter, Bruker Corporation, and T2 Biosystems.